Study of age and immune response to pneumococcal vaccine
Part of Immune system & allergy clinical trials.
This study is looking at how age affects the immune system's response to a pneumococcal vaccine. Researchers want to compare younger and older adults to see if immune cells change with age.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 21–40 years old or 65+ years old (some people over 60 may also qualify if needed)
- You have never received a pneumococcal (pneumonia) vaccine
- You have had no acute infections in the past 2 weeks (like cold, flu, stomach bug)
- You have not taken any anti-inflammatory medicine (like ibuprofen, aspirin) in the past week
- You have not had any alcohol in the past 24 hours
- You do not have an immune deficiency, chronic infections, or certain chronic diseases (like poorly controlled heart or metabolic conditions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the immune system works in older adults and how it relates to infections. It aims to develop better ways to prevent and manage infectious diseases in people over 60.
This study is for people living with HIV who are 18 or older and on HIV medication. Researchers want to learn how the immune system and vaccine response change as people age, and will give a pneumococcal (pneumonia) vaccine to study that.
This study tests a new pneumococcal vaccine to see if it is safe and triggers a good immune response. It may help protect you from infections like pneumonia, but you must not have had any pneumococcal vaccine since age 5.
This study looks at how the immune system in the nose and throat reacts to Streptococcus pneumoniae bacteria and viruses in adults aged 60-85. It may help researchers find better ways to prevent or treat pneumonia.
This study tests a pneumococcal vaccine designed for 20 types of bacteria in older adults who are hospitalized with suspected community-acquired pneumonia. It aims to see how the vaccine works in real-world care and whether it affects how pneumonia happens or progresses.
This trial tests whether a pneumococcal vaccine can help protect against a specific type of pneumonia bacteria. Researchers want to see if the vaccine can create antibodies that work against multiple strains.
Hear when a new Aging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.